Listen Here:
Click or simply search “Sigma Nutrition” on your podcast platform of choice.
Or listen directly on the Sigma website here.
Introduction
Omega-3 fatty acids (particularly EPA and DHA) have a long history in nutrition and cardiovascular medicine, yet the clinical trial literature is often perceived as inconsistent. This episode examines why some randomized trials show clear benefit while others show null or mixed findings, and how differences in trial design, dose, population risk, and outcome selection can materially change what we observe.
A key theme is separating (1) the persistent cultural narratives around omega-3s (including origin stories that do not hold up well to modern evidence) from (2) the more precise, mechanistic and clinical questions about where supplemental EPA/DHA may reduce cardiovascular risk. The discussion focuses heavily on understanding heterogeneity: why “omega-3 supplementation” is not a single, uniform exposure, and why subgroup patterns (e.g., secondary prevention, higher baseline triglycerides, and higher doses) may explain much of the apparent conflict in the evidence.
Note: This discussion is taken from a previous episode of the podcast. The audio has been remastered and improved, and now study notes and full transcript are available.
Related resources
- Join the Sigma newsletter for free
- Subscribe to Sigma Nutrition Premium
- Become a member of Alan Flanagan’s Alinea Nutrition Education Hub
- Enroll in the next cohort of our Applied Nutrition Literacy course
- Studies referenced:
- Related episodes:
- [04:10]Omega-3 historical context and Inuit studies
- [08:38]Mechanisms of omega-3 benefits
- [12:49]VITAL and ASCEND trials analysis
- [23:41]GISSI-Prevenzione trial insights
- [26:44]REDUCE-IT trial and residual risk
- [32:19]Significance of baseline triglycerides
- [37:57]2018 Cochrane review
- [33:23]Impact of Training Schedules on Sleep
- [46:02]Hu et al. meta-analysis
- [01:00:27]Practical takeaways for omega-3 supplementation
- [01:03:55]Key ideas segment (premium subscribers only)
The Hosts
Click through to your app of choice to listen and subscribe:
Dr. Alan Flanagan has a PhD in nutrition from the University of Surrey, where his doctoral research focused on circadian rhythms, feeding, and chrononutrition.
This work was based on human intervention trials. He also has a Masters in Nutritional Medicine from the same institution.
Dr. Flanagan is a regular co-host of Sigma Nutrition Radio. He also produces written content for Sigma Nutrition, as part of his role as Research Communication Officer.
Danny Lennon has a master’s degree (MSc.) in Nutritional Sciences from University College Cork, and he is the founder of Sigma Nutrition.
Danny is currently a member of the Advisory Board of the Sports Nutrition Association, the global regulatory body responsible for the standardisation of best practice in the sports nutrition profession.
Introduction to this Episode
Omega-3 fatty acids (particularly EPA and DHA) have a long history in nutrition and cardiovascular medicine, yet the clinical trial literature is often perceived as inconsistent. This episode examines why some randomized trials show clear benefit while others show null or mixed findings, and how differences in trial design, dose, population risk, and outcome selection can materially change what we observe.
A key theme is separating (1) the persistent cultural narratives around omega-3s (including origin stories that do not hold up well to modern evidence) from (2) the more precise, mechanistic and clinical questions about where supplemental EPA/DHA may reduce cardiovascular risk.
The discussion focuses heavily on understanding heterogeneity: why “omega-3 supplementation” is not a single, uniform exposure, and why subgroup patterns (e.g., secondary prevention, higher baseline triglycerides, and higher doses) may explain much of the apparent conflict in the evidence.
